Advertisement

Cost-utility analysis, the pearl in the crown

      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Canadian Journal of Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hodge W
        • Brown A
        • Kymes
        • et al.
        Pharmacologic management of neovascular age-related macular degeneration: systematic review of economic evidence and primary economic evaluation.
        Can J Ophthalmol. 2010; 45: 223-230
        • Sharma S
        • Brown GC
        • Brown MM
        • Hollands H
        • Shah GK
        The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
        Ophthalmology. 2001; 108: 2051-2059
        • Rosenfeld PJ
        • Brown DM
        • Heier JS
        • et al.
        • MARINA Study Group
        Ranibizumab for neovascular age-related macular degeneration.
        N Eng J Med. 2006; 355: 1419-1431
        • Brown DM
        • Kaiser PK
        • Michels M
        • et al.
        • ANCHOR Study Group
        Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
        N Engl J Med. 2006; 355: 1432-1444
        • Brown GC
        • Brown MM
        • Sharma S
        Difference between ophthalmologist and patient perceptions of quality-of-life associated with age-related macular degeneration.
        Can J Ophthalmol. 2000; 35: 27-32
        • Stein JD
        • Brown MM
        • Brown GC
        • Sharma S
        • Hollands H
        Quality of life with macular degeneration.Perceptions of patients, clinicians and community members.
        Br J Ophthalmol. 2003; 87: 8-12
      1. Guidelines for the economic evaluation of health technologies: Canada. 3rd ed. Canadian Agency for Drugs and Technologies in Health, Ottawa, Ont.2006 (Accessed April 20, 2010)
        • Javitt JC
        • Zhou Z
        • Willke RJ
        Association between visual loss and higher medical care costs in Medicare beneficiaries.
        Ophthalmology. 2007; 114: 238-245
        • Brown MM
        • Brown GC
        • Brown HC
        • Irwin B
        • Roth Z
        Comparative effectiveness and cost-effectiveness analyses of VEGF-A inhibitor and 90Sr brachytherapy for neovascular macular degeneration.
        Evid Based Ophthalmol. 2009; 10: 107-122
        • Schmier JK
        • Halpern MT
        • Covert D
        • Delgado J
        • Sharma S
        Impact of visual impairment on use of care giving by individuals withage-related macular degeneration.
        Retina. 2006; 26: 1056-1062
      2. Center for Preventive Ophthalmology and Biostatistics. Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
        (Accessed April 20, 2010.)
        • Brown MM
        • Brown GC
        • Sharma S
        Evidence-Based to Value-Based Medicine. American Medical Association Press, Chicago, Ill.2005: 93-266